Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4%

Invivyd, Inc. (NASDAQ:IVVD) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 35,613,115 shares, a growth of 24.4% from the December 15th total of 28,634,579 shares. Currently, 20.5% of the shares of the stock are short sold. Based on an average trading volume of 5,706,265 shares, the short-interest ratio is currently 6.2 days. Based on an average trading volume of 5,706,265 shares, the short-interest ratio is currently 6.2 days. Currently, 20.5% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IVVD. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Cantor Fitzgerald initiated coverage on shares of Invivyd in a report on Monday, October 6th. They set an “overweight” rating and a $10.00 price objective on the stock. D. Boral Capital restated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. D Boral Capital downgraded Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, BTIG Research initiated coverage on Invivyd in a research report on Monday, December 22nd. They issued a “buy” rating and a $10.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Insider Buying and Selling at Invivyd

In other news, Director Kevin F. Mclaughlin acquired 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average cost of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director directly owned 50,000 shares of the company’s stock, valued at approximately $125,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 25.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd in the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC lifted its position in Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares in the last quarter. Bank of America Corp DE boosted its stake in Invivyd by 330.5% during the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after buying an additional 37,811 shares during the last quarter. SG Americas Securities LLC acquired a new position in Invivyd during the fourth quarter worth $60,000. Finally, Invesco Ltd. grew its holdings in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after buying an additional 71,485 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Price Performance

Invivyd stock traded up $0.01 during trading hours on Monday, hitting $2.45. 1,802,177 shares of the stock traded hands, compared to its average volume of 3,340,812. Invivyd has a 1 year low of $0.35 and a 1 year high of $3.07. The stock has a market capitalization of $571.14 million, a price-to-earnings ratio of -5.21 and a beta of 0.61. The firm’s 50 day moving average price is $2.41 and its 200-day moving average price is $1.60.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.The company had revenue of $13.13 million during the quarter, compared to analysts’ expectations of $12.00 million. Research analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.